Systemic therapy without radiation may be appropriate as neoadjuvant therapy for localized pancreas cancer

作     者：Scott Kizy Ariella M.Altman Keith M.Wirth Schelomo Marmor Jane Y.C.Hui Todd M.Tuttle Emil Lou Khalid Amin Jason W.Denbo Eric H.Jensen Scott Kizy;Ariella M. Altman;Keith M. Wirth;Schelomo Marmor;Jane Y. C. Hui;Todd M. Tuttle;Emil Lou;Khalid Amin;Jason W. Denbo;Eric H. Jensen

作者机构：Division of Surgical OncologyDepartment of SurgeryUniversity of MinnesotaMinneapolisMNUSA Division of Hematology and OncologyDepartment of Internal MedicineUniversity of MinnesotaMinneapolisMNUSA Department of Laboratory Medicine and PathologyUniversity of MinnesotaMinneapolisMNUSA 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2020年第9卷第3期

页      面：296-303页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：This work was supported by the following funding:Ariella Altman is in part supported by the Institute of Basic and Applied Research in Surgery and the VFW fund of the University of Minnesota.Keith Wirth is supported by National Institutes of Health/National Institute of Diabetes and Digestive Kidney Diseases T32DK108733(MPI:Yamamoto and Beilman) 

主　　题：Pancreatic adenocarcinoma chemotherapy survival neoadjuvant chemotherapy resection 

摘      要：Background:The utility of neoadjuvant treatment for resectable pancreas cancer is yet to be determined,but has commonly included *** evaluated outcomes in patients with radiographically resectable pancreatic adenocarcinoma treated with neoadjuvant chemotherapy without ***:A retrospective review of patients in our institutional pancreatic cancer registry was performed,which identified 36 patients who received neoadjuvant chemotherapy alone for resectable pancreatic adenocarcinoma between 2012 and ***:Median age at diagnosis was 66.3 *** regimens included gemcitabine(n=17),gemcitabine/nab-paclitaxel(n=8),or 5-FU/leucovorin/irinotecan/oxaliplatin(FOLFIRINOX)(n=11).Surgical resection was performed in 69%of patients(n=25),with an R0 resection rate of 92%(n=23 patients).During chemotherapy,distant disease became apparent in 19%of patients(n=7),while no patients had evidence of local *** rates were similar between chemotherapy regimens(single agent=59%,multiple agent=79%).Median overall survival for all patients who received neoadjuvant chemotherapy was 30.3 and 34.4 months for those who underwent surgical *** was no difference in median survival for patients treated with gemcitabine(31.3 months)or multi-agent chemotherapy(29.7 months).Conclusions:A short course of neoadjuvant chemotherapy without chemoradiation may improve patient selection prior to surgical resection for pancreas ***,local disease progression did not limit surgical resection in this small series.